The Effects of Pre-transplant Dialysis Modality on Post-transplant Events
PDMP
1 other identifier
observational
1,040
1 country
1
Brief Summary
This is a prospective, multicenter, comparative, parallel-group, observational study. There will be 2 cohorts according to pre-transplant dialysis modality (hemodialysis or peritoneal dialysis). In each cohort, subjects will be observed for 12 months. Approximately, 1040 subjects will be enrolled from 8 transplant centers. Subjects will be enrolled consecutively until the number of subjects in peritoneal dialysis group has been 260. It will take 2 years. In this period, the number of subject in hemodialysis group enrolled in this study will be 780. After finishing the observation of all subjects, to balance clinical and demographic baseline characteristics between the two groups, subjects will be selected in each cohort with 1:1 matched using propensity score method. And then primary and secondary endpoints will be compared between two groups.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2011
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 22, 2011
CompletedFirst Submitted
Initial submission to the registry
January 16, 2012
CompletedFirst Posted
Study publicly available on registry
January 20, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedApril 27, 2017
April 1, 2017
5.7 years
January 16, 2012
April 25, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
composite outcomes (delayed graft function, functional delayed graft function, primary nonfunction, biopsy-proven acute rejection)
1. Delayed graft function 2. Functional DGF (defined as the absence of a decrease in serum creatinine level by a minimum of 10% per day during 3 consecutive days in the first postoperative week, not including patients in whom acute rejection, calcineurin inhibitor toxicity, or both, developed within the first week 3. Primary nonfunction 4. Biopsy proven acute rejection
1 year posttransplant
Secondary Outcomes (4)
eGFR
1 year
Hospitalization
1 year
graft loss
1 year
Subject death
1 year
Study Arms (2)
Hemodialysis group
Hemodialysis group
peritoneal dialysis group
peritoneal dialysis group
Eligibility Criteria
primary care clinic
You may qualify if:
- Subjects must have end-stage renal disease, have been on one renal replacement therapy (hemodialysis or peritoneal dialysis) for \> 6 months ( Who had been on hemodialysis for at least 6 months before renal transplant for the hemodialysis group; Who had been on peritoneal dialysis for at least 6 months before renal transplant for the peritoneal dialysis group ), and are scheduled to receive a first kidney transplant from a deceased donor, a living-related donor, or a living-unrelated donor.
- Between the ages of 20 and 70 years, inclusive.
- Either female or male adults
- Subjects must be willing and able to provide written personal information consent with evidence of a personally signed and dated personal information consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
You may not qualify if:
- Subjects who had combined dialysis (hemodialysis + peritoneal dialysis simultaneously).
- Subjects who are recipients for multiple organ transplant.
- Subjects scheduled for non-heart beating donor transplantation.
- Subjects scheduled for transplantation using desensitization (plasmapheresis + Rituximab) process.
- Subjects with evidence of active infection.
- Women of childbearing potential who are either pregnant, lactating, planning to become pregnant in the next 12 months. Women of childbearing potential must be willing to agree to contraceptive practices.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ha Young Ohlead
- Baxter Healthcare Corporationcollaborator
Study Sites (1)
Samsung Medical Center
Seoul, 135-710, South Korea
Study Officials
- PRINCIPAL INVESTIGATOR
Hayoung Oh
South Korea Samsung Medical Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
January 16, 2012
First Posted
January 20, 2012
Study Start
December 22, 2011
Primary Completion
September 1, 2017
Study Completion
December 1, 2017
Last Updated
April 27, 2017
Record last verified: 2017-04